# An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

> **NCT01386580** · PHASE1,PHASE2 · COMPLETED · sponsor: **BBB-Therapeutics B.V.** · enrollment: 84 (actual)

## Conditions studied

- Brain Metastases
- Lung Cancer
- Breast Cancer
- Melanoma
- Malignant Glioma

## Interventions

- **DRUG:** 2B3-101
- **DRUG:** Trastuzumab
- **DRUG:** 2B3-101 60 mg/m2 every 4 weeks
- **DRUG:** 2B3-101 50 mg/m2 every 3 weeks

## Key facts

- **NCT ID:** NCT01386580
- **Lead sponsor:** BBB-Therapeutics B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2015-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01386580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01386580, "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01386580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*